A Study of the Safety and Efficacy of Omarigliptin (MK-3102) in ≥18 and <45 Year-Old Participants With Type 2 Diabetes Mellitus and Inadequate Glycemic Control (MK-3102-028)
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 203 participants.
Also called NCT01814748
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 203 participants
- Sponsor
- Registry
-
NCT01814748 -
2012-004303-12
-
- Other papers using this trial's data
- Use of Prohibited Medication, a Potentially Overlooked Confounder in Clinical Trials: Omarigliptin (Once-weekly DPP-4 Inhibitor) Monotherapy Trial in 18- to 45-year-olds
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- Not reported
- Registry status
- Completed
Technical summary
Registry record NCT01814748. Randomized; double masking; primary purpose treatment. Start 2013-05-03 (actual); primary completion 2015-09-14 (actual). Results posted on 2016-07-18.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study of the Safety and Efficacy of Omarigliptin (MK-3102) in ≥18 and <45 Year-Old Participants With Type 2 Diabetes Mellitus and Inadequate Glycemic Control (MK-3102-028)
- Condition
- Diabetes Mellitus
- Intervention (Drug)
- Omarigliptin
- Intervention (Drug)
- Placebo to omarigliptin
- Intervention (Drug)
- Metformin
- Lead sponsor
- Merck Sharp & Dohme LLC
Record details
- Record id
cardio:ct-nct01814748- Content hash
d943d0d9eb3c6669bdf75f949e9286cf9ee64849fa825c21f7aee62786859c0d